

Press Release
August 17, 2023

Data from PANTAX trial to be presented at ESMO Congress 2023

Safety data from the PANTAX trial, studying SCO-101 in pancreatic cancer, has been accepted for poster presentation.

Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, will have clinical safety data for its lead compound SCO-101 presented at the European Society for Medical Oncology (ESMO) Congress 2023 taking place in Madrid on October 20-24, 2023. This will be a good opportunity for Scandion to make the safety data available to a large number of international physicians and other stakeholders.

Safety data from the PANTAX phase 1b trial in patients with pancreatic cancer will be announced at a poster presentation at the congress. This data will provide details to the topline results communicated in March 2023.

The primary endpoint of the PANTAX trial was achieved as the maximum tolerated dose of SCO-101 in combination with standard of care chemotherapies gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer was established at 200 milligrams given for 6 consecutive days every 2 weeks.

Scandion expects to perform a full analysis of all safety and efficacy outcomes late in 2023 with the final data to be presented in H1 2024.

For further information please contact:

Johnny Stilou, CFO
Phone: +45 2960 3532
E-mail: jos@scandiononcology.com

The information was provided by the contact person above for publication on August 17, 2023, at 08.30 CET.

Scandion Oncology (Scandion), the Cancer Drug Resistance Company, discovers and develops first-in-class medicines aimed at treating cancer which is resistant to current treatment options. We are at the forefront of this field, developing novel medicines that address cancer's resistance against treatment. Our aim is to make existing cancer treatments work better and longer, thereby potentially prolonging and improving the life of patients who would otherwise have a high risk of dying from their cancer.

Globally, close to 10 million patients die every year from cancer and approximately 90 percent of all cancer related deaths are due to cancer drug resistance. Our medicines could be relevant in several different cancers. That makes both our medical and commercial potential significant.

Scandion is based in Copenhagen and its lead candidate, SCO-101, is currently being studied in clinical phase I and II trials. The company is listed on Nasdaq First North Growth Market Sweden (ticker: SCOL).

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market.